Discover Great Companies Discover Great Clients
Popularity  10.3万   |   Followers  22   |   Likes  4   |   Feedback  20 Claim this company

Infusion quality bears the trust of life, with responsibility heavier

No.178 Qingdao City Popularity Ranking No.31 Laoshan District No.642 Shandong P No.1 Organic Raw Materials No.2 APIs No.2 Yi Yao Jing Ji No.2 Health Technology No.2 Pharmaceutical APIs No.3 Healthcare Supplies No.3 Medical Devices No.3 Medical Products No.4 Packaging Materials No.5 Dai Processing No.8 Health Products No.9 Zhi Yao / Yao Industries 名牌产品 企业技术中心 守合同重信用企业 院士工作站 省级五一劳动奖 常务理事单位 GMP认证
More

Company Overview

  • Nature: Public Listed Company Size: 1000-4999 employees Founded: 28年
  • Industry: Pharmaceutical/Biotechnology Engineering
  • Full name: HuaRen Pharmaceutical Co., Ltd.。

Development Stage

  • Stage: IPO上市, 创业板, 深交所。
  • Ranking: Ranked #178 in Qingdao City by popularity Ranked #1 in Qingdao Organic Raw Materials Company by popularity Ranked #2 in Qingdao APIs Company by popularity Ranked #2 in Qingdao Yi Yao Jing Ji Company by popularity Ranked #2 in Qingdao Health Technology Company by popularity
  • Honors: 2023中国高新技术企业慈善公益500强 名牌产品 企业技术中心 According to algorithm
  • News: 2025-07-30:华仁药业:子公司取得一次性使用腹透置管手术包医疗器械注册证。
  • Salary: 50% of positions earn 6-10K, In 2026 vs last yeargrew by 48%.。Master's salary: ¥18.0K.
  • R&D: "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 8.3%, "Medical & Health/Beauty & Healthcare": 6.1%, "Other (R&D and Technical)": 5.3%。
  • Recruiting: In 2026 vs 2025decreased by 55%. Demand for highly educated talent: Master's: 2.
  • Requirement: Education: 本科 leads with 56.8%. Experience: 不限 leads with 32.6%.
  • Region: Distributed across 2 regions, 青岛: 79.5%, 合肥: 10.6%, 濮阳: 1.5%, 广州: 1.5%.

About the Company

[Summary] Infusion quality bears the trust of life, with responsibility heavier

Founded in May 1998, HuaRen Pharmaceutical is a modern pharmaceutical and health industry group integrating research and development, production, and sales, focusing on preparations, active pharmaceutical ingredients (APIs), pharmaceutical packaging materials, and medical devices.
In August 2010, the company was successfully listed on the Shenzhen Stock Exchange with the stock abbreviation "HuaRen Pharmaceutical" and stock code "300110". In July 2019, the company underwent an equity change, and the Administrative Committee of Xi'an Qujiang New District became the actual controller of the company.
After more than two decades of development, the company's business focuses on nephrology, respiratory, psychotropic and anesthetic, and large-volume preparations. It has successively established five major production bases in Qingdao, Rizhao, Xiaogan, Pubei, and Hefei, with a total production capacity of 950 million bags (bottles). All production lines have passed the new GMP certification. The company's main products include small-volume injections, peritoneal dialysis solutions, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting pharmaceutical packaging, health products, and APIs. Currently, it has 106 varieties and 220 specifications of drugs, including pentazocine injection, doxofylline injection, glycerol fructose sodium chloride injection, and low-calcium peritoneal dialysis solution, achieving integrated development of "API + preparation + pharmaceutical packaging material".
With innovation as the soul of development, in recent years, the company has actively seized strategic development opportunities, focusing on treatment directions in nephrology, respiratory, psychotropic and anesthetic, as well as the screening of new varieties such as large-volume preparations. Benchmarking against first-class domestic and international enterprises, the company continues to increase R&D investment, enrich its R&D pipeline, diversify product lines, and enhance sustainable development capabilities. As of the end of 2023, HuaRen Pharmaceutical and its subsidiaries have obtained a total of 508 authorized patents, including 103 invention patents. Among them, the wholly-owned subsidiary Hengxing Pharmaceutical is one of the 50 national designated manufacturers of Class II psychotropic drug APIs.
Among them, the peritoneal dialysis solution product holds the leading market share among domestic brands.
Through more than 20 years of exploration and practice, the company has successively received honors such as "National Key Technical Transformation 'Double High and One Excellent' Project", "National Intellectual Property Advantage Demonstration Enterprise", "Shandong Province Pharmaceutical Industry Excellent Enterprise for the 60th Anniversary of the Founding of the People's Republic of China", "Shandong Province Quality Management Award", "Shandong Famous Brand Products", "Shandong Province High-end Brand Cultivation Enterprise", and "Excellent Product Brand for Respiratory System". In 2020, the company was awarded the "2020 National Market Quality Credit AA Level (User Satisfaction Enterprise)" honor by the China Association for Quality. In 2022, the company received the "Shandong Province May Day Labor Certificate". In 2024, it has been honored for five consecutive years as one of the "Top 100 Chinese Pharmaceutical Industry", ranking 71st.
In the future, the company will actively respond to the national "Healthy China" strategy, supported by product capability building, and through the combination of independent R&D and collaborative innovation, actively promote the strategic layout of pharmaceutical and health. It is committed to growing into a pharmaceutical and health industry group with comprehensive synergistic development across segments such as APIs, preparations, medical devices, and pharmaceutical packaging materials.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

HuaRen Pharmaceutical Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market: 创业板
  • Deal: 深交所

HuaRen Pharmaceutical How Fast Is Hiring Growing? (25 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 29%
  • 2024: Up 295%
  • 2023: Up 90%
  • 2022: Down 78%
HuaRen Pharmaceutical Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
HuaRen Pharmaceutical Campus Recruitment & Advanced Degree Talent Demand
Master's 2
Note: How fast is hiring at HuaRen Pharmaceutical Co., Ltd. growing? HuaRen Pharmaceutical2026: 88 openings (down 55%), 2025: 194 openings (up 29%), 2024: 150 openings (up 295%), 2023: 38 openings (up 90%), 2022: 20 openings (down 78%), 2021: 93 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

HuaRen Pharmaceutical Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 200%
  • 2024: Flat 0%-
HuaRen Pharmaceutical Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at HuaRen Pharmaceutical Co., Ltd. growing? HuaRen PharmaceuticalMaster's recruitment over the years: 2025: 3 openings (up 200%), 2024: 1 openings (flat), 2023: 1 openings, 2021: 3 openings.

HuaRen Pharmaceutical R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at HuaRen Pharmaceutical Co., Ltd.? Based on an analysis of HuaRen Pharmaceutical's job postings over the past year, "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 8.3%, "Medical & Health/Beauty & Healthcare": 6.1%, "Other (R&D and Technical)": 5.3%, "Mechanical/Instrumentation": 4.5%, "Scientific Research": 1.5%, "Computer/Network/Technology": 1.5%. For reference only.

HuaRen Pharmaceutical — What Are the Salaries Like? (132 records)

Manage
HuaRen Pharmaceutical Salary Overview
salary range: 3K - 50K, 50% of roles pay ¥6-10K
Note: salary statistics are based on 132 salary records from the past year and depend on the job sample. For reference only.
How is the salary at HuaRen Pharmaceutical Co., Ltd.?HuaRen Pharmaceutical50% of positions earn 6-10K, Undergraduate salary: ¥。Qingdao salary ranking top 35,Business Management average salary ¥19.6K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of HuaRen Pharmaceutical

(More)
Are salaries high at HuaRen Pharmaceutical Co., Ltd.? We provide: Legal Counsel, Sales, Management Trainee, QA, Corporate Communications Specialist, Finance Specialist, Accountant, Operator, General Worker, Maintenance Worker, Pharmaceutical R&D, IT Director, Instrument Engineer, Corporate Culture Specialist, Laboratory Technician, Auditor, Marketing, General Manager, Editor, BP. Click to view detailed salary analysis by job.

HuaRen Pharmaceutical — Fortune 500? (More)

Yes, ranked in 中国高新技术企业慈善公益500强:

  • NO.417 2023中国高新技术企业慈善公益500强 >

Job Category

  • Business Management
    15.2% of total 15.2%
  • Finance/Audit/Statistics
    13.6% of total 13.6%
  • Sales
    13.6% of total 13.6%
  • Marketing/PR/Media
    12.9% of total 12.9%

Education

  • 本科
    56.8% of total 56.8%
  • 大专
    27.3% of total 27.3%
  • 不限
    9.1% of total 9.1%
  • 硕士
    4.5% of total 4.5%

Experience

  • 不限
    32.6% of total 32.6%
  • 3-5年
    31.1% of total 31.1%
  • 1-3年
    23.5% of total 23.5%
  • 5-10年
    12.9% of total 12.9%
View Detailed Analysis

What does HuaRen Pharmaceutical Co., Ltd. require? Who is HuaRen Pharmaceutical hiring? HuaRen Pharmaceutical recruitment: Business Management占比最多占15.2%,其次是Finance/Audit/Statistics占13.6%. What education can get in at HuaRen Pharmaceutical? 本科占比最多占56.8%,其次是大专占27.3%. High education required at HuaRen Pharmaceutical? 硕士占4.5%. Work experience required at HuaRen Pharmaceutical? 不限占比最多占32.6%,其次是3-5年占31.1%. Where are the job locations at HuaRen Pharmaceutical? 青岛占比最多占79.5%,其次是合肥占10.6%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 118,221.2982万(元)
Legal Representative: 陈志国
Date Established:
Credit Code: 91370200706426601X
Registered Address: 青岛市高科技工业园株洲路187号

HuaRen Pharmaceutical Featured in the Following Albums (More)

Partners & Suppliers

为公司提供年度财务报表审计服务 Source
供应商 审计服务
作为公司非PVC多层共挤膜的主要供应商,为公司提供输液软袋包材 Source
供应商 包装材料
作为公司前五大供应商之一,向公司供应葡萄糖等原料药 Source
供应商 原料药
作为公司前五大客户之一,直接采购大输液、腹膜透析液等产品 Source
合作客户 医院终端
作为公司前五大客户之一,向公司采购大输液等产品 Source
合作客户 医药流通

People who follow HuaRen Pharmaceutical also follow

HuaRen Pharmaceutical Competitors (Similar Companies)

“Carrying expectations, strict management, perseverance, and pursuit of”
“一家自有核心技术与产品的智能物流和智能制造解决方案提供商”
压铸 铝制品 数控/CNC 铸造
建材 钢结构 轻钢 彩钢板
农机链 摩托车链 摩托车 汽车零部件/配件
轨道交通装备 生产 轨道交通技术 国有资本
新材料 金属丝 金属丝绳 制造
合金钢 高温合金 型钢 合金材料
油锯 割灌机 绿篱剪 汽油机
智能制造/生产/加工 制冷 制冷配件 管路
“Making a Good Tire”
“贝克曼沃玛作为全球主要风能发电设备制造企业的A级供应商”
“R&D, production, sales and supporting services of cutting equipment an”
“主营业务为酶制剂、微生态、动物保健品的研发、生产和销售”

Discover Great Companies, Discover Great Clients

青岛公司名录 青岛“Laoshan District”公司名录 青岛“医药工业”公司名录 青岛“原料药”公司名录 青岛“大健康”公司名录 青岛“医疗器械”公司名录 青岛“代加工/OEM”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates